Targeting breast cancer with hormonal treatment options.
Mellington
Terrie E
TE
University of Pittsburgh, USA.
Fields
Margaret M
MM
D000359:Aftercare; D000553:Ambulatory Care; D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use*; D006801:Humans; D007255:Information Services; D020407:Internet; D000077289:Letrozole; D009570:Nitriles / Q000627:therapeutic use; D009722:Nurse Practitioners; D018579:Patient Selection; D017698:Postmenopause; D017410:Practice Guidelines as Topic; D011960:Receptors, Estrogen / Q000187:drug effects; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole; D000077289:Letrozole; C056516:exemestane